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Abstract
Neurohumoral stimulation comprising both autonomic-nervous-system dysfunction and activation
of hormonal systems including the renin-angiotensin-aldosterone system (RAAS) was found to be
associated with Type-2-diabetes (T2D). Therapeutic strategies such as RAAS interference proved
to be beneficial in both T2D treatment and prevention. In addition to an activated RAAS,
hyperleptinemia in obesity, hyperinsulinemia in conditions of peripheral insulin resistance and
overall oxidative stress in T2D represent known activators of the sympathetic component of the
autonomic nervous system. Here, we hypothesize that sympathetic activation may cause peripheral
insulin resistance defined as partial blocking of insulin effects on glucose uptake. Resulting
hyperinsulinemia or hyperglycemia-related oxidative stress may further aggravate sympatho-
excitation. This notion leads to a secondary hypothesis: sympathetic activation worsens from
obesity towards insulin resistance, and further towards T2D. In this review, existing evidence
relating to neurohumoral stimulation in T2D and consequences thereof, such as oxidative stress
and inflammation, are discussed. The aim of this review is to provide a rationale for therapies, which
are able to intercept neuroendocrine pathways in T2D and precursor states such as obesity.
Background
Both Type-2-Diabetes (T2D) and Chronic Heart Failure
(CHF) may be perceived as consequences of originally
diverse pathologies. In the CHF condition, the diagnosis
of ischemic or non-ischemic etiology does not imply a dif-
ferent prognosis nor, with exception of antiarrhythmic
strategies, treatment modality. Likewise, except for pan-
creatic-islet-transplant issues, the fundamental and
adjunctive therapies for long standing, insulin-dependent
T2D are the same, regardless the underlying reasons for
T2D. Once advanced stages of T2D have been reached, dif-
ferent etiologies, i.e. genetically or environmentally
caused T2D, appear of less importance to disease manage-
ment and prognosis. Therefore, uniform disease mecha-
nisms pertinent for disease progression in T2D need to be
identified. As such a mechanism, neurohumoral stimula-
tion comprising autonomic-nervous-system (ANS) dys-
function, i.e. sympathetic activation and vagal
deactivation, as well as activation of hormones such as the
renin-angiotensin-aldosterone system (RAAS) may be
considered. The concept of neurohumoral stimulation
was first applied to CHF, where plasma norepinephrine
[1], atrial natriuretic peptide [2], B-type natriuretic pep-
tide [3] and endothelin-1 [4] were found to be correlated
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with mortality or severity of disease. In T2D neurohu-
moral stimulation exists as well. There, ANS dysfunction
[5] and the RAAS [6,7] are critically involved. In addition,
neurohumoral stimulation may involve adipose-tissue
hormones given that obesity is one risk factor for T2D [8]
as well as gastrointestinal neuropeptidergic inputs [9].
Hormone actions may affect insulin sensitivity, oxidative
stress, inflammation and endothelial function (Table 1)
as well as the ANS (Table 2).
Presentation of the hypothesis
We hypothesize that persistent sympathetic-nervous-sys-
tem activation actually represents one cause of peripheral
insulin resistance (IR) defined as partial blocking of insu-
lin effects on glucose uptake emphasizing oxidative stress
and inflammation as possible links between neurohu-
moral stimulation and IR.
Testing the hypothesis
First, T2D-relevant hormones and the ANS are reviewed.
Second, consequences of neurohumoral stimulation such
as oxidative stress and inflammation are highlighted with
regard to IR.
Insulin
Beyond the hypoglycemic action, insulin activates the
sympathetic nervous system, while withdrawing the vagal
component of the ANS [10,11]. Furthermore, insulin
enhances endothelial nitric-oxide synthase (eNOS) [12]
which determines microvascular tone and may neutralize
reactive oxygen species (ROS). We hypothesize that ANS
dysfunction in terms of sympathetic activation, from
whatever source, deteriorates peripheral insulin sensitiv-
ity, thus leading to repetitive hyperinsulinemia and hyper-
glycemia. If this hypothesis holds true, resulting
hyperinsulinemia may further activate the sympathetic
component of the ANS. Moreover, as hallmarks of type-2
diabetes, continued hyperinsulinemia may lead to pan-
creatic beta-cell exhaustion [15], while repetitive hyperg-
lycemia may increase oxidative stress [13,14].
Adipokines
Obesity is a major risk factor for T2D [16]. Adipokines
such as leptin, resistin and adiponectin seem to be
involved in IR. As stated in Figure 1, hyperleptinemia
occurring in obesity directly activates the sympathetic
nervous system [17-19]. Leptin increases oxidative stress
[20], however, it may further attenuate interleukin activa-
tion [21]. Both leptin and resistin serum levels have been
found to be associated with IR [22]. Conversely, the duo-
Table 1: Hormone effects on insulin sensitivity, oxidative stress, inflammation and endothelial function.
Insulin Sensitivity Oxidative Stress Inflammatory response Endothelial cell function
Insulin NA ↓ [12] ? ↑ [12]
Angiotensin 2 ↓ [45] ↑ [44] ↑ [46] ↓ [49]
Aldosterone ↓ [52] ↑ [53] ↑ [53] ↓ [54]
Epinephrine ↓ [28] ↑ [37] ↑ [38] ?
Norepinephrine ↓ [28] ↑ [37] ↑ [39] ?
Endothelin 1 ↓ [62] ↑ [59], [60] ↑ [61] ↓ [58]
Leptin ↓ [22] ↑ [20] ↓ [21] ↓ [20]
Consequences of hormone actions on oxidative stress, inflammatory responses, and endothelial-cell dysfunction were summarized from published 
evidence. Arrows indicate the direction of hormone-mediated changes, question marks indicate unknown effects.
Table 2: Hormone effects on the autonomic nervous system.
Sympathetic function Vagal function
Insulin ↑ [10] ↓ [11]
Angiotensin 2 ↑ [42] ↓ [43]
Aldosterone ? ↓ [55]
Leptin ↑ [17] ?
Sympathetic effects of hormones were derived from published evidence either from direct nerve recordings or power-spectral analysis of heart 
rate (low-frequency band). Vagal effects of hormones were assumed when heart rate variability was demonstrated to increase or when changes in 
the high-frequency band of power-spectral analysis of heart rate occurred. Arrows indicate the direction of the hormone-mediated changes, 
question marks indicate unknown effects.Cardiovascular Diabetology 2004, 3 http://www.cardiab.com/content/3/1/4
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denum-derived ghrelin [9] and adiponectin [23,24] were
demonstrated to correlate with insulin sensitivity. ANS
effects of resistin, adiponectin or of ghrelin are currently
unknown. However, on endothelial cells, resistin pro-
motes the release of endothelin-1 [25], known to be sym-
patho-excitatory [26]. Besides the possible role of
adipokines on the ANS, cellular and subcellular adipocyte
signalling issues may yield further insight into the special
role of abdominal obesity for T2D [27].
Catecholamines
Catecholamines deteriorate insulin sensitivity as shown
by high plasma concentrations of catecholamines in phe-
ochromocytoma patients. There, insulin sensitivity was
restored by tumor-removal surgery [28]. On the molecular
level β-adrenergic stimulation itself inhibits insulin sign-
aling molecules such as insulin receptor substrates, which
have been shown to be essential for insulin action [29-
31]. Furthermore, expression of adiponectin is inhibited,
whereas IR-inducing IL-6 is stimulated by β-adrenergic
activation in fat cells [32,33]. However, beta-adrenergic
receptor blocking drugs have not shown any effect on
insulin sensitivity [34]. Both metabolic counteractive
effects of beta-adrenergic blockade on pancreas-islet func-
tion and possibly still-active sympathetic stimulation via
autonomic nerve fibers [35] may explain the lack of effect
of beta-adrenergic blockade on IR. However, third-gener-
ation, vasodilating beta-blocking agents may set off possi-
ble adverse metabolic effects and confer a benefit for
individuals having IR [36] bearing in mind that actions of
epinephrine and norepinephrine include pro-oxidative
[37] and proinflammatory effects [38,39].
Relationships between known risk factors for T2D, neurohumoral factors and consequences thereof including oxidative stress  and inflammatory response leading to peripheral IR and T2D Figure 1
Relationships between known risk factors for T2D, neurohumoral factors and consequences thereof including oxidative stress 
and inflammatory response leading to peripheral IR and T2D. Blue arrows represent stimulation pathways, green arrow repre-
sents inhibition.
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Renin-Angiotensin-Aldosterone System
Recent studies demonstrate the beneficial nature of thera-
peutic angiotensin-2 blockade in T2D using either angi-
otensin-converting-enzyme (ACE) inhibitors or direct
angiotensin-2, subtype-1 receptor (AT1) antagonists
[7,40,41]. Several mechanisms may account for this. First,
angiotensin 2 acts as a sympathetic-nervous-system acti-
vator [42] and as a deactivator of vagal function [43]. Sec-
ondly, the activation of the RAAS facilitates the generation
of free ROS via a NADPH-oxidase mechanism [44], lead-
ing to oxidative injury [45] and IR. Furthermore,
angiotensin 2 elicits a pro-inflammatory, monocytic
response [46]. Conversely, the blockade of the RAAS elic-
its a reduction of oxidative stress [47], a decrease of CRP
as a marker of inflammation [48], a restoration of
endothelial function [49], and an increase of adiponectin
concentration [50], indicating an adipocyte-mediated
amelioration of insulin sensitivity [23].
Aldosterone may independently contribute to adverse
effects, given the observation, that aldosterone release
may "escape" an ACE-inhibition or AT1 blockade [51].
Pharmacological or surgical correction of hyperaldos-
teronism has been shown to improve insulin sensitivity
[52]. Moreover, an elevated plasma aldosterone is associ-
ated with pro-inflammatory and pro-oxidative effects [53]
and may confer endothelial dysfunction [54]. Indirect evi-
dence suggests aldosterone to be associated with an atten-
uated vagal [55] and cardiac sympathetic function [56].
However, especially for aldosterone effects on the sympa-
thetic nervous system, there is no conclusive evidence
available, yet.
Endothelin-1
Endothelin-1 is a most potent, mainly endothelially
derived vasoconstrictor. Endothelin-1 concentrations
were found to be increased in T2D [57]. Endothelin-
receptor-A blockade improves endothelial dysfunction in
T2D and obesity [58]. Moreover, chronic endothelin-1
application is associated with elevated oxidative stress
[59,60], inflammatory reaction within the arterial wall
[61] and IR [62]. The principle of endothelin-1 blockade
may, therefore, have beneficial effects in patients with
T2D. Those effects may include an attenuation of preva-
lent sympatho-excitation as shown in the CHF condition
[26].
Autonomic-nervous-system dysfunction as a cause of 
insulin resistance
Paradoxically, ANS dysfunction in terms of an activation
of the sympathetic nervous system either increases or
blunts insulin sensitivity. On the one hand, sympathetic
activation may increase energy expenditure [63] and
mediate lipolysis [64], thereby possibly reducing over-
weight as beta adrenergic blockade implies [65]. Thus,
sympathetic activation may primarily serve as a compen-
satory mechanism. On the other hand, too much sympa-
thetic activation may lead to IR: caffeine, eliciting
sympathetic activation, has been shown to diminish
peripheral-tissue insulin sensitivity [66]. Pheochromocy-
toma patients clearly have IR due to the high plasma con-
centrations of norepinephrine [28], and non-diabetic
patients with sympatho-excitation due to spinal-chord
injury were shown to have IR [67]. Moreover, heart-rate
recovery following exercise-capacity tests as a measure of
vagal function and predictor of cardiovascular mortality
[68], correlates with insulin sensitivity [69]. Thus, once
sympatho-activation or vagal deactivation is persistent,
deleterious consequences such as IR may occur. Therefore,
we hypothesize that sympatho-excitation, i.e. persistent
sympathetic activation, may cause IR either directly via
signalling effects within target cells or, indirectly, via oxi-
dative-stress induced inflammatory responses. The atten-
uation of sympatho-excitation by centrally acting
antiadrenergic drugs such as moxonidin slightly reduced
IR [70] as a further indication of the validity of our
hypothesis.
Mechanistically, a reduced nitric-oxide (NO) availability
may be involved in the evolution of sympatho-excitation
given the fact that certain eNOS polymorphisms are con-
comitant with a higher T2D and IR susceptibility [71].
Besides cardiovascular NO effects, central-nervous system
NO may exert sympatho-inhibitory effects [72,73].
Furthermore, life-style modifications such as exercise may
restore ANS function in T2D or in precursor states via res-
toration of cardiovascular reflexes [74]. External factors,
such as ethanol and tobacco consumption may further
contribute to oxidative stress [75,76] or sympathetic-nerv-
ous-system activation [77,78].
The individual players of the overall concept of neurohu-
moral stimulation must still be characterized. As Figure 1
shows, the known T2D risk factors may ultimately affect
the sympathetic nervous system, the RAAS and oxidative-
stress milieu, once antioxidant pathways are saturated.
Oxidative stress and insulin resistance
Oxidative stress is a candidate mechanism connecting
neurohumoral stimulation with IR [79], involving either
an activated, vascular-smooth-muscle NADPH oxidase
[44] or uncoupled nitric-oxide synthase. Those sources of
"internal" oxidative-stress may be therapeutic targets.
Other sources of internal oxidative stress, such as cyto-
chrome-c leakage of superoxide anion, may be involved in
(as well being the reason for) oxidative-stress sequelae
such as carbonylation of proteins as seen in T2D [80].
Besides subcellular effects on insulin signalling [81], oxi-
dative stress may lead to an activation of cytokines [82,83]Cardiovascular Diabetology 2004, 3 http://www.cardiab.com/content/3/1/4
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as well as to an activation of the sympathetic nervous sys-
tem [84], possibly via desensitized afferent fibers of the
sympatho-inhibitory baroreflex [85]. Thus, once RAAS-
mediated oxidative stress is not compensated, another
vicious cycle begins, aggravating IR towards T2D. Accord-
ing to Figure 2, it appears to be important to intervene in
the possible vicious cycles involving the activation of the
RAAS and the sympathetic nervous system. As both ACE
inhibitors and AT1 antagonists interfere with the RAAS,
hydroxy-methyl-glutaryl-CoA-reductase inhibitors or stat-
ins may have the potential to attenuate sympatho-excita-
tion [73,86] possibly by preventing NADPH oxidase
activation as a source of endogenous oxidative stress
[14,87]. In both type-1 and type-2-diabetes mellitus, the
latter drug clearly improved outcomes [88], however, per-
oral antioxidants did not [89]. One may argue that oxida-
tive stress associated with T2D, atherosclerosis and
hypertension is therapeutically accessible solely by drugs
affecting internal sources of oxidative stress such as statins
[88] or AT1 blockade [41]. Besides inflammation,
vasodilatory or endothelial dysfunction may be another
consequence of enhanced oxidative stress by ROS scav-
enging endothelial-cell derived nitric oxide [90].
Inflammation and insulin resistance
Inflammatory responses are likely to be due to oxidative-
stress mediated alterations of cytokine expression includ-
ing interleukin-6 [83]. Interleukin-6, in turn, elicits a CRP
release from the liver [91]. The principle of ROS-mediated
inflammation has been demonstrated using ultraviolet
light [92,93]. Although more research is needed, this sug-
gested relationship may underly the inflammatory
Suggested therapeutic interventions with regard to the framework of T2D risk factors and neurohumoral factors given in Fig- ure 1 Figure 2
Suggested therapeutic interventions with regard to the framework of T2D risk factors and neurohumoral factors given in Fig-
ure 1. Solid lines across empty arrows signify blocked pathways; dotted lines across solid arrows represent attenuated 
pathways.
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responses seen in atherosclerosis, obesity, and T2D. Prev-
alent inflammation may at least partially explain the
occurrence of IR amid neurohumoral stimulation given
the known roles of cytokines and of acute-phase reactants
in IR [94,95]. In fact, inflammation has been shown to be
one risk factor for T2D [96]. As yet another proposed
vicious cycle, repetitive hyperglycemia due to IR may fur-
ther aggravate the oxidative stress [14] as well as the
cytokine-mediated inflammatory response (Figure 1).
Implications of the hypothesis
The summarized evidence suggests that neuroendocrine
mechanisms participate in T2D evolution. Neurohumoral
stimulation is likely to be an important cause for the oxi-
dative-stress milieu, the state of inflammation, and insu-
lin resistance. Therefore, we propose the hypothesis that
ANS dysfunction, most likely sympathetic-nervous-sys-
tem activation, represents one cause of IR likely to be
mediated by oxidative-stress induced inflammation. For
both T2D treatment and prevention, this hypothesis may
serve as a rationale for both pharmaceutical and non-
pharmaceutical interventions to restore ANS tone and
insulin sensitivity. Treatments, that are likely to affect ANS
tone and insulin sensitivity may include RAAS interfer-
ence, statin therapy, endothelin antagonism, or weight-
control programs through exercise and/or hypocaloric
diet (Figure 2). Because IR is difficult to measure, a practi-
cal approach may involve non-diabetic individuals having
'metabolic syndrome' [97]. Metabolic syndrome implies a
24.5-fold elevated risk for incidence of T2D [98] probably
due to an underlying peripheral IR. Disturbed autonomic
activity in terms of sympathetic activation and vagal deac-
tivation may be a candidate mechanism for both the con-
version processes of obesity to metabolic syndrome and
of metabolic syndrome to T2D. Overall, clinical studies in
T2D patients as well as in patients at risk for the develop-
ment of T2D should determine ANS surrogates, such as
muscle sympathetic nerve activity or heart rate variability,
to further elucidate the role of ANS dysfunction in T2D
evolution.
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